Search Results - "PARADISO, PETER R"

Adult indication 13-valent pneumococcal conjugate vaccine clinical development overview: formulation, safety, immunogenicity (dosing and sequence), coadministration, and efficacy by Fletcher, Mark A, Schmoele-Thoma, Beate, Vojicic, Jelena, Daigle, Derek, Paradiso, Peter R, Del Carmen Morales, Graciela

“…There was no 13-valent pneumococcal conjugate vaccine (PCV13) adult antibody concentration threshold regulatory criterion for licensure - unlike the pediatric…”
Get full text

Advances in Pneumococcal Disease Prevention: 13-Valent Pneumococcal Conjugate Vaccine for Infants and Children by Paradiso, Peter R.

“…A 13-valent pneumococcal conjugate vaccine (PCV13), developed with the same chemistry used for the 7-valent PCV vaccine (PCV7) and with the goal of expanding…”
Get full text

Safety and Immunogenicity of Heptavalent Pneumococcal Vaccine Conjugated to CRM197 in United States Infants by Rennels, Margaret B, Edwards, Kathryn M, Keyserling, Harry L, Reisinger, Keith S, Hogerman, Deborah A, Madore, Dace V, Chang, Ih, Paradiso, Peter R, Malinoski, Frank J, Kimura, Alan

“…To determine the safety and immunogenicity of heptavalent pneumococcal saccharide vaccine (serotypes 4, 6B, 9V, 14, 18C, 19F, 23F) individually conjugated to…”
Get full text

Pneumococcal Conjugate Vaccine for Adults: A New Paradigm by Paradiso, Peter R.

“…A 13-valent pneumococcal conjugate vaccine has been studied in adults aged ≥50 years to compare the immune response to that induced by the 23-valent…”
Get full text

Establishing Government-Operated Vaccine Programs: An Industry Perspective by Paradiso, Peter R

“…During 2000–2002, shortages of numerous routinely administered pediatric vaccines occurred. The reasons for these shortages were varied, but they included…”
Get full text

Pneumococcal conjugate vaccine in adults: Let's see what happens by Paradiso, Peter R.

“…The recent recommendation for the use of the 13-valent pneumococcal conjugate vaccine (PCV13) in adults 65 y of age and older, provides a new tool for…”
Get full text

Safety and Immunogenicity of a Purified F Protein Respiratory Syncytial Virus (PFP-2) Vaccine in Seropositive Children with Bronchopulmonary Dysplasia by Groothuis, Jessie R., King, Susan J., Hogerman, Debbie A., Paradiso, Peter R., Simoes, Eric A. F.

“…Respiratory syncytial virus (RSV) causes serious respiratory illness in preterm children with bronchopulmonary dysplasia. In a prospective randomized…”
Get full text

Which Pneumococcal Serogroups Cause the Most Invasive Disease: Implications for Conjugate Vaccine Formulation and Use, Part I by Hausdorff, William P., Bryant, John, Paradiso, Peter R., Siber, George R.

“…We analyzed >70 recent data sets to compare the serogroups causing invasive pneumococcal disease (IPD) with those represented in conjugate vaccine…”
Get full text

Challenges in Estimating Efficacy Against Pneumococcal Pneumonia in Children by Center, Kimberly J, Paradiso, Peter R

Get full text

Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children by Hausdorff, William P, Siber, George, Paradiso, Peter R

“…The development of glycoconjugate vaccines for Streptococcus pneumoniae that are effective in very young children has renewed interest in identification of…”
Get full text

The Contribution of Specific Pneumococcal Serogroups to Different Disease Manifestations: Implications for Conjugate Vaccine Formulation and Use, Part II by Hausdorff, William P., Bryant, John, Kloek, Carolyn, Paradiso, Peter R., Siber, George R.

“…To assess whether certain serogroups of Streptococcus pneumoniae are preferentially associated with specific disease manifestations, we analyzed all recent…”
Get full text

Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers by SHINEFIELD, HENRY R, BLACK, STEVEN, RAY, PAULA, CHANG, IH, LEWIS, NED, FIREMAN, BRUCE, HACKELL, JILL, PARADISO, PETER R, SIBER, GEORGE, KOHBERGER, ROBERT, MADORE, DACE V, MALINOWSKI, FRANK J, KIMURA, ALAN, LE, CHINH, LANDAW, IRENE, AGUILAR, JANET, HANSEN, JOHN

“…OBJECTIVES.The objectives of this study were (1) to determine the safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate (PNCRM7) vaccine in…”
Get full text

Safety and immunogenicity of four doses of Neisseria meningitidis group C vaccine conjugated to CRM197 in United States infants by RENNELS, MARGARET B, EDWARDS, KATHRYN M, KEYSERLING, HARRY L, REISINGER, KEITH, BLATTER, MARK M, QUATAERT, SALLY A, MADORE, DACE V, CHANG, IH, MALINOSKI, FRANK J, HACKELL, JILL G, PARADISO, PETER R

“…BACKGROUND.Following widespread use of conjugate pneumococcal vaccine, Neisseria meningitidis likely will become the leading cause of bacterial sepsis and…”
Get full text

Recent progress in the development of vaccines for infants and children by McIntosh, E.David G, Paradiso, Peter R

“…Infectious agents do not respect national or international boundaries. Attempts to prevent their spread, and the diseases which they cause, involve…”
Get full text

Conjugate Vaccines for Streptococcus pneumoniae by Peter R Paradiso

Get full text

The future of polio immunization in the United States: are we ready for change? by PARADISO, PETER R

“…During the past 6 months there has been considerable debate within the infectious disease community about the current and future recommendations for polio…”
Get full text

Safety and immunogenicity of a combined diphtheria, tetanus, pertussis and Haemophilus influenzae type b vaccine in young infants by PARADISO, P. R, HOGERMAN, D. A, MADORE, D. V, KEYSERLING, H, KING, J, REISINGER, K. S, BLATTER, M. M, ROTHSTEIN, E, BERNSTEIN, H. H, HACKELL, J

“…To study the safety and immunogenicity of a combined diphtheria-tetanus-pertussis (DTP)-Haemophilus influenzae type b (HbOC) vaccine (TETRAMUNE) in infants as…”
Get full text

Combined Childhood Immunizations by Paradiso, Peter R

“…To the Editor.—The recent article by Clemens et al1 states the need for care when assessing potential interference in combination of or even simultaneous…”
Get full text

The immunogenicity of Haemophilus influenzae type b conjugate (HbOC) vaccine in human immunodeficiency virus-infected and uninfected infants by Kale, K L, King, Jr, J C, Farley, J J, Vink, P E, Cimino, C O, Paradiso, P R

“…Enzyme-linked immunosorbent assay polyribosyl ribitol phosphate (PRP) antibody responses to Haemophilus influenzae type b conjugate vaccine (HbOC) given at 2,…”
Get more information

Establishing government-operated vaccine programs : An industry perspective: Strengthening the supply of routinely administered vaccines in the United States by PARADISO, Peter R

Get full text